Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028
Sponsored by: GlobalData
- Awareness And Treatment
Date: 22 August
Days to go: 5
Time: 3PM London/10AM New York
Emerging Biologicals will Grow the HS Market by Increasing Awareness and Treatment Rates for HS
Hidradenitis Suppurativa (HS) is characterized as a disease with some of the highest unmet needs in immunology. There is a lack of therapies available on the market and currently Humira (adalimumab) is the only approved biologic available for HS patients, which was approved for HS in 2015 in the US.
Due to the high unmet needs in HS, four companies are developing therapies for HS that are in the late-stage pipeline. Promising therapies being developed for HS include Novartis’ Cosentyx, Xbiotech’s bermekimab, InflaRX’s IFX-1, and ChemoCentryx’s avacopan. All of these agents are targeted for moderate and severe patients and are expected to drive growth of the HS market, as current treatment options are limited. In addition, adalimumab biosimilars are expected to launch during the forecast period and are set to negatively impact the sales of Humira. This will allow for increased competition in the HS market by impacting Humira’s first to market status. Overall, the HS market will increase during the forecast period due to the entrance of these four pipeline agents and increased uptake of therapeutics, as increasing awareness will promote diagnosis of HS and drive increased treatment rates, growing the HS market.
In this webinar Vikesh Devila, Analyst at GlobalData, will present an analysis of the overall HS pipeline with an emphasis on addressing patient groups of high unmet need (i.e., moderate to severe HS patients), by drawing on insights from GlobalData’s recently published report, Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028. An analysis of the currently available Humira will be provided as well as evaluations of emerging biological immunomodulators. Some of the promising pipeline agents will be profiled in detail. Michael Breen, Associate Director at GlobalData, will moderate a Q&A session following the presentation.
Vikesh Devila, PhD,
Vikesh Devila, PhD, is an Analyst for the Immunology Therapy team at GlobalData in London. He is currently responsible for providing expert insight and detailed reports in the Immunology space with an emphasis on disease market and therapy forecasting. He has over seven years of research experience in immunology and in academic and pharmaceutical laboratories at the Anthony Nolan Research Institute, University College London, and King’s College London. At UCL and the Anthony Nolan Research Institute, he earned his PhD investigating immune reconstitution in cord blood transplantation. Prior to his PhD he worked in clinical research and investigated the presence of biomarkers on monocytic cells before and after treatment with Humira in arthritic patients.
Associate Director, Infectious Diseases
Michael Breen, PhD, is the Associate Director of Infectious Diseases at GlobalData in Boston. He has over a five years of experience in market analysis, business intelligence, and providing strategic insight for the pharmaceutical industry. Prior to his current role, he was a Senior Analyst for Decision Resources Group, where he gained extensive experience writing in-depth reports and developing forecasts for a variety of indications, including rare and infectious diseases and vaccines. Michael has a BA in biology and biochemistry from Hunter College, and a PhD in biochemistry from Boston University School of Medicine.
Key Learning Objectives
- Learn how GlobalData has assessed the potential impact of pipeline therapeutics targeting HS
- Gain insight into which biologics GlobalData deems to be the most promising for HS
- Assess the HS pipeline by stage of development and type of intervention
- Learn which companies are most advanced for development of potential HS-addressing agents
- Managers/Senior Managers/Associate Directors/Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers